UNSPSC 51285603: Delmopinol

This classification denotes a surface-active agent with the molecular formula C16H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DT67WL708F, chemically known as 4-morpholineethanol, 3-(4-propylheptyl)-, ( -)- but more generally known as delmopinol, which bears U.S. National Institutes of Health Compound Identifier 57337. European Medicines Agency schedules Delmopinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06956MIG.

UNSPSC 51285603 Delmopinol, a Commodity code, sees minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities posted under this code do not reflect delmopinol purchases; instead, they document pharmaceutical warehouse contracts for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and emergency medical supplies (naloxone and drug deactivation systems). State and local health departments and county public health authorities are the issuing bodies, but the actual goods being procured diverge substantially from the code's product definition. The Illinois Department of Public Health awarded a $2,999,999.11 multi-year pharmaceutical warehouse contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC for antibiotic tablets; Seminole County, Florida issued a competitive IFB for naloxone and safe drug deactivation systems for community health delivery.

Activity under this code shows sparse, scattered coverage with no clear concentration of repeat buyers or sustained procurement momentum. The geographic spread spans Illinois and Florida, with no evidence of broader state or regional activity. The code's tagging appears misaligned with actual purchasing intent — neither the Illinois antibiotic warehouse supply nor the Seminole County naloxone procurement represents delmopinol sourcing. Vendors evaluating this code should verify that state and local health procurement offices are actually buying delmopinol as a discrete product line; the current opportunity record provides no actionable signal for pursuit.